CD33 and acute myeloid leukemia: 225Ac-lintuzumab (Actimab-A) is a radioimmunoconjugate composed of 225Ac linked to a humanized anti-CD33 monoclonal antibody that is currently being studied in untreated older AML patients unfit for intensive chemotherapy.